Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
3.390
+0.200 (6.27%)
At close: Sep 26, 2025, 4:00 PM EDT
3.180
-0.211 (-6.21%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Onconetix Revenue
Onconetix had revenue of $106.49K in the quarter ending June 30, 2025, a decrease of -84.89%. This brings the company's revenue in the last twelve months to $1.33M, down -9.35% year-over-year. In the year 2024, Onconetix had annual revenue of $2.52M with 4,217.31% growth.
Revenue (ttm)
$1.33M
Revenue Growth
-9.35%
P/S Ratio
0.58
Revenue / Employee
$265,392
Employees
5
Market Cap
5.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.52M | 2.47M | 4,217.31% |
Dec 31, 2023 | 58.47K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ONCO News
- 1 day ago - Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. - GlobeNewsWire
- 1 day ago - Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement - GlobeNewsWire
- 5 days ago - Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM - GlobeNewsWire
- 2 months ago - Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement - GlobeNewsWire
- 3 months ago - Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewsWire
- 3 months ago - Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders - GlobeNewsWire
- 4 months ago - Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewsWire
- 4 months ago - Onco-Innovations Uplists to Cboe Canada - Business Wire